What You Need to Know
Hackensack University Medical Center, Center for Memory Loss and Brain Health will be participating in a multicenter clinical trial to study the safety and efficacy of escitalopram, an antidepressant, for the treatment of agitation related to Alzheimer’s disease.
This study is sponsored by the National Institute on Aging. Johns Hopkins University is the principal site and Hackensack University Medical Center will begin enrolling patients in the study starting in September 2021.
Patients may be eligible for the study if they have received a diagnosis of Alzheimer’s disease, and experience frequent agitation or aggression.
The study will last approximately six months. Patients will be randomized to receive either the study drug (escitalopram) or placebo (an inactive substance) in pill form.